Overview of Ketoflex

Quick Facts

Property	Description
Active Ingredients	Ketoprofen, Thiocolchicoside
Form	Oral Tablet, Topical Gel, Injectable Solution
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID) and Muscle Relaxant Combination
General Purpose	Short-term management of acute musculoskeletal pain and spasm
Origin	Synthetic/Semi-synthetic Derivative

What Type of Medicine is Ketoflex and How is it Classified?

Ketoflex is precisely classified as a fixed-dose combination drug that provides two distinct therapeutic actions in one formulation. It is categorized as a medication combining a Nonsteroidal Anti-Inflammatory Drug (NSAID) and a muscle relaxant. The active constituents are Ketoprofen, a synthetic derivative, and Thiocolchicoside, a semi-synthetic derivative of colchicine. This dual classification reflects its intended use against pain that involves both inflammation and concurrent muscle stiffness, a profile that involves multimodal relief. This specific combination provides a structured approach to managing complex acute pain profiles.

Ketoprofen and Thiocolchicoside: Composition and Synergistic Benefit

The composition of Ketoflex provides a synergistic effect through its two primary components. Ketoprofen works to reduce pain and inflammation by inhibiting the production of pain-causing chemical messengers. Thiocolchicoside then acts centrally to relieve muscle spasm and stiffness. The unique advantage of this combination is its capacity to simultaneously target both the underlying source of inflammation and the secondary muscle guarding. Using Thiocolchicoside alongside an NSAID, such as Ketoprofen, is intended to address both pain and muscle spasms simultaneously. This dual action provides a comprehensive approach to the resolution of acute musculoskeletal discomfort. The medicine is prepared for various administration needs, commonly as an oral tablet for systemic use, but also as a topical gel or an injectable solution.

What side effects are possible with Ketoflex?

Possible Side Effects and Safety Information

Ketoflex (a non-steroidal anti-inflammatory drug or NSAID) carries warnings regarding potentially serious risks based on governmental regulatory findings. The drug’s safety profile centers on the potential for severe cardiovascular (CV) and gastrointestinal (GI) adverse events.

Serious and Clinically Significant Risks

Cardiovascular Thrombotic Events: Use may increase the risk of serious, potentially fatal, CV thrombotic events, including myocardial infarction (heart attack) and stroke. The risk may increase with duration of use. The drug is contraindicated for the relief of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Risk: NSAIDs increase the risk of serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur without warning symptoms.
Other Serious Reactions: Documented risks include severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), serious hepatotoxicity, new onset or worsening hypertension, and renal toxicity (e.g., acute renal failure).

Adverse Reaction Categories

Common side effects generally involve the gastrointestinal system (e.g., nausea, vomiting, indigestion, abdominal pain, heartburn) and the central nervous system (headache, dizziness, drowsiness).

Less Common reactions include bladder pain, difficult or painful urination, and certain skin rashes.

Safety Restrictions and Populations

Ketoflex is contraindicated in patients with a history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs. Use is generally not recommended in the third trimester of pregnancy due to risks to the fetus. Caution and monitoring are advised for elderly patients and individuals with pre-existing conditions such as hypertension, heart failure, kidney disease, or liver disease, as they may be at a greater risk for serious adverse events.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for the components of Ketoflex by documenting the potential for serious systemic complications and the requirement for immediate professional intervention.

Documented Overdose Manifestations

Overdose may present with documented gastrointestinal and central nervous system effects. The signs commonly listed in official labeling include epigastric pain, nausea, vomiting, and diarrhea. Central nervous system manifestations may include lethargy, drowsiness, somnolence, and confusion.

Severe Outcomes and Required Emergency Action

A suspected overdose necessitates immediate medical attention due to the potential for severe or life-threatening systemic outcomes documented in official sources. Serious manifestations include gastrointestinal bleeding, ulceration, and perforation, as well as acute renal failure, hepatic dysfunction, coma, or seizures. The documentation requires users to contact emergency services or a poison control center immediately for guidance. The official labeling specifies that elderly patients are at a greater risk for these serious gastrointestinal complications.

Management and Monitoring

Management is primarily restricted to symptomatic and supportive treatment, as no specific antidote is known for the NSAID component. Following exposure, hospital monitoring and assessments of vital signs, alongside specific diagnostic procedures (such as laboratory tests or ECGs), are procedures listed in the official overdose management instructions.

Therapeutic Uses of Ketoflex

What Ketoflex Treats: Main Uses and Benefits

Ketoflex is used to provide symptomatic support in acute musculoskeletal situations where symptoms related to physical discomfort are combined with symptoms of increased muscular activity. Its therapeutic approach is relevant for easing painful contractures. The muscle relaxant component is applied in addressing painful muscle contractures associated with acute spinal pathology.

The medicine is commonly used to help manage acute episodes presenting with heightened symptoms, such as lumbago (acute lower back pain), sciatica, neck myofascial pain syndrome, and post-traumatic or post-operative contractures. It assists with managing symptom clusters that may become intense or disruptive. The medication is applied across therapeutic domains where short-term symptomatic assistance is needed to address both pain and muscle tension. By addressing these spasms, the medication may assist with easing distress and supports functional stability during the acute phase.

Quick Fact: Relief for Acute Discomfort
Targeted Use	Conditions presenting with heightened symptoms and muscle spasm
Key Benefit	Contributes to improved comfort and supportive relief by easing physical discomfort and contractures

Eligibility and Restrictions for Use

Ketoflex is authorized for use only in adults and adolescents 16 years of age or older. Its systemic use is strictly restricted to short-term treatment of acute conditions, and it is officially not recommended for the long-term management of chronic pain.

The medicine is contraindicated and must not be used by several populations. These include pregnant women, breastfeeding women, and women of childbearing potential not using effective contraception, due to significant safety concerns raised by regulatory authorities regarding the Thiocolchicoside component. Use is also formally prohibited in the pediatric population under 16 years of age.

Absolute contraindications also apply to individuals with severe heart failure, severe renal failure, active peptic ulcer disease, or a history of gastrointestinal bleeding. Furthermore, the medicine is contraindicated in patients with a history of seizure disorders or known hypersensitivity to Ketoprofen, Thiocolchicoside, or other NSAIDs. Elderly patients and those with mild-to-moderate liver or kidney impairment require close monitoring and special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific drug–drug, substance, and condition-related restrictions for Ketoflex (Ketoprofen + Thiocolchicoside). These constraints focus on mitigating additive risks and preventing pharmacokinetic interference.

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	NSAIDs, Anticoagulants, Antiplatelet Agents, Diuretics, ACE Inhibitors/ARBs, Lithium, Methotrexate, CNS Depressants, other Muscle Relaxants.
Specific interacting medicines (if explicitly listed)	Lithium, Methotrexate, Aspirin, Warfarin, Heparin.

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is officially contraindicated due to the significantly increased risk of gastrointestinal bleeding and ulceration. Use is also contraindicated during pregnancy and in women of childbearing potential not using effective contraception due to the genotoxicity risk associated with a Thiocolchicoside metabolite. Consumption of alcohol is restricted due to its potential to intensify CNS depression and increase bleeding risk.

The medicine is officially documented to increase the plasma concentrations of Lithium and increase the exposure of Methotrexate by interfering with renal clearance. Concomitant use with anticoagulants and antiplatelet agents carries a documented risk of bleeding and hemorrhage. Caution is warranted when co-administered with diuretics or antihypertensive agents (ACE inhibitors/ARBs), which may impair the antihypertensive effect and increase the risk of renal function deterioration. Monitoring of renal function is required when used in patients with renal impairment or when combined with nephrotoxic drugs.

Mechanism of Action

Peripheral Modulation of Prostaglandin Synthesis

This mechanistic domain is centered on Ketoprofen's ability to non-selectively inhibit the COX-1 and COX-2 enzymes, thus interfering with the biosynthesis of PGE2 and other prostaglandins within the Arachidonic Acid Cascade . By modifying the early molecular steps in this cascade, the mechanism results in a decreased level of mediators that typically lower the activation threshold of peripheral nociceptors and are associated with localized extravasation of fluid.

Central Inhibition of Spinal Motor Reflexes

The second domain involves Thiocolchicoside, whose action is primarily central and not peripheral. Its key mechanism involves interacting as an agonist with Glycine receptors in the spinal cord, a key component of the inhibitory neurotransmitter system. This engagement helps modulate central motor tone by promoting chloride ion influx, which results in a quantifiable decrease in motor neuron excitability associated with pathological muscle hypertonia.

Dual-Site Physiological Modulation

The combination mechanism engages two separate physiological systems: the peripheral inflammatory pathway and the central neuromuscular control pathway. This dual-site modulation initiates or suppresses signaling sequences across both systems, resulting in a combined physiological effect that influences both localized chemical signaling and central motor reflex dynamics.

Dosage and Administration Information

How to use Ketoflex

Ketoflex (Ketoprofen/Thiocolchicoside) is intended for short-term use only, with strict limitations placed on the duration of therapy and maximum dosage. The medicine is supplied in several forms, including oral tablets, topical gel, and an injectable solution, allowing for systemic or localized application.

Administration Guidelines

Parameter	Administration Parameters
Routes	Oral, Intramuscular (IM), and Topical.
Frequency	Twice daily (BID), maintaining an interval of approximately 12 hours between doses.
Oral Dosing	The dose of the muscle relaxant component must not exceed 8 mg per single intake, or a maximum of 16 mg per day.
IM Dosing	The dose of the muscle relaxant component must not exceed 4 mg per single injection, or a maximum of 8 mg per day.
Duration Limit	Oral use is limited to a maximum of 7 consecutive days. IM use is limited to a maximum of 5 consecutive days.

Procedural Context and Constraints

For oral administration, tablets should be swallowed with a glass of water. While the Ketoprofen component's total absorption is not significantly altered by food, the daily dosage must adhere strictly to the specified limits.

The medicine is only authorized for use in adults and adolescents 16 years of age and older. This strict age minimum is a constraint regarding the patient population. Adherence to the maximum duration and daily dose is required, as the medicine is intended solely for a brief course of therapy.

Recent Clinical Evidence

Overview of Studies for Ketoflex

Evidence for use in Acute Non-Specific Low Back Pain

Ketoflex was evaluated in research exploring conditions associated with acute, non-specific low back pain, often referred to as lumbago. The core evidence for this fixed-dose combination (FDC) therapy comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews, which compared the FDC against using only the NSAID component (Ketoprofen) or a placebo. The studies monitored changes in patient-reported outcomes describing perceived discomfort and examined outcomes reflecting daily functioning or activity level. Studies conducted during periods of increased symptom activity reported patterns related to how symptoms evolved in the observed populations over the short treatment period. Research highlights changes measured during the study period concerning physical discomfort and functional capacity.

Evidence for use in Acute Musculoskeletal Pain with Spasm

The combination was studied for clinical trials focusing on musculoskeletal conditions where outcomes related to physical discomfort are associated with painful muscle contractures, such as those related to acute spinal issues. These studies monitored how symptoms changed over time in conditions involving periods of heightened symptoms. Findings indicate patterns related to the intensity of muscle spasm and patient mobility as observed during the study period. The evidence contributes to the broader evidence landscape for dual-agent regimens.

Study Consistency and Research Gaps

The existing research base is characterized by some degree of variability and inconsistency across the different primary trials, meaning findings were mixed in the broader research landscape. Follow-up durations were typically limited, not extending beyond 5 to 7 days, which means long-term effects are not fully established. Further comparative evidence is lacking against all other established comparative therapies, and data for certain groups, such as older adults or pediatric patients, remain insufficient.

Key Studies & References Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature

Frequently Asked Questions (FAQ)

Common questions about Ketoflex (FAQ)

Q: How quickly can I expect Ketoflex to start working?

Regulatory information that describes how the body processes the medicine indicates that the muscle relaxant component, Thiocolchicoside, is measured at its highest level in the blood about 30 minutes after an intramuscular injection. Following oral administration, the main active metabolite reaches its peak concentration around 1 hour. This data describes the rate at which the drug enters your system.

Q: Does taking Ketoflex affect the results of common lab tests?

Official regulatory documents indicate that this medicine can potentially affect laboratory test results related to renal function (how well the kidneys are working). For example, it is documented to increase Blood Urea Nitrogen (BUN) levels in some cases. Close monitoring of renal function is advised for elderly patients and individuals with pre-existing kidney conditions.

Q: How is the safety of Ketoflex monitored after it is approved?

This medicine is subject to additional monitoring by regulatory authorities such as the EMA. This process allows them to quickly identify any new safety information or risks that may emerge after the drug is used by the general population. Healthcare professionals are officially asked to report any suspected adverse reactions.

Q: How long does the effect of one dose of Ketoflex usually last?

While the official documentation does not give a specific duration of effect, the standard regulatory guidelines for its use indicate that the oral dose is to be taken twice daily (BID). This dosing schedule is based on an interval of approximately 12 hours between each dose.

Q: Can Ketoflex be taken with common over-the-counter pain relievers?

Regulatory documents explicitly state that this medicine is contraindicated (must not be used) with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) due to the significantly increased risk of serious side effects, such as gastrointestinal bleeding. It is important to understand the classification of any pain reliever before use.

Q: What is the maximum duration of use cited in clinical trials for Ketoflex?

The existing clinical research that evaluated this combination medicine is characterized by limited follow-up durations. These studies typically did not extend beyond 5 to 7 days. This is consistent with why official use is strictly restricted to short-term treatment of acute conditions.

Q: Does Ketoflex have any known long-term side effects?

Official studies and information indicate that the long-term effects of this combination medicine are not fully established. This is because the clinical trials supporting its use were limited to very short follow-up durations, typically not exceeding 5 to 7 days. It is officially not recommended for the long-term management of chronic pain.

Q: Are there any specific foods or drinks to avoid while using Ketoflex?

Official regulatory documents specify that alcohol consumption is restricted while using this medicine. This is because alcohol has the potential to intensify Central Nervous System (CNS) depression and increase the risk of bleeding. For oral administration, tablets are described in the guidelines as being swallowed with a glass of water.

Q: Are there different strengths or versions of Ketoflex?

Yes, the medicine is supplied in several different forms, including oral tablets, a topical gel, and an injectable solution. Additionally, the oral tablets of the muscle relaxant component are officially available in two different strengths: 4 mg and 8 mg.

Q: Why do some people experience [general side effect, e.g., drowsiness] when starting Ketoflex?

Drowsiness is listed as a commonly reported side effect of this medicine. The muscle relaxant component, Thiocolchicoside, is designed to act on the central nervous system (CNS). This central action to relieve muscle spasm is associated with potential side effects like dizziness and drowsiness.

Q: Is it true that Ketoflex can be used for conditions not mentioned in the official uses?

Official regulatory documentation defines the medicine's General Purpose as the short-term management of acute musculoskeletal pain and spasm. Regulatory content defines its scope based on the approved indication and does not discuss or support any use outside of that official purpose.

Q: What is the official definition of the condition Ketoflex is approved to treat?

According to official product information, the medicine is indicated as an 'adjuvant treatment' (meaning used in addition to other therapy) for painful muscle contractures related to acute spinal pathology. This use is restricted to adults and adolescents aged 16 years and older.

Q: How does the risk profile of Ketoflex compare to its benefits, according to regulators?

Regulatory authorities have determined the medicine is authorized for use in the short-term management of acute conditions. This reflects a regulatory judgment that the known serious risks are balanced by the medicine's short-term benefit only when the mandated maximum duration and dosage limits are observed.

Q: Where can I find the official prescribing information for Ketoflex?

The complete, authoritative information for this medicine is published by regulatory bodies as the Summary of Product Characteristics (SmPC) in Europe or the Prescribing Information/DailyMed document in the US.

Q: Does Ketoflex affect a person's ability to drive or operate machinery?

Drowsiness is listed as a commonly reported side effect. Official product information notes that this potential for drowsiness should be considered by individuals before driving a vehicle or operating machinery.

Q: Does Ketoflex cause weight gain or loss?

Regulatory documentation for the NSAID component lists weight gain as a rare side effect that has been observed in some studies. Weight loss has also been reported as an adverse reaction, though its frequency is not specifically noted.

Q: Are there known interactions between Ketoflex and recreational substances?

Alcohol consumption is restricted due to its potential to intensify CNS depression and increase the risk of bleeding. The official documents detailing drug interactions typically only list specific medicines and substances with documented regulatory concerns.

Q: Is Ketoflex used in other countries besides the US?

Yes, this medicine combination is approved and regulated by governmental bodies outside of the US. For instance, it is monitored by the European Medicines Agency (EMA) and other international regulatory authorities, indicating its use and regulation in various countries.

Q: Are there special warnings for people with a history of stomach ulcers when using Ketoflex?

The medicine is contraindicated (must not be used) in patients who have active peptic ulcer disease. Since the medicine is an NSAID, official warnings state that it carries a documented risk of serious gastrointestinal adverse events, including bleeding and ulceration, which can occur even without prior warning symptoms.

How should Ketoflex be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines strictly define the conditions necessary to maintain the stability and safety of Ketoflex. These conditions must be followed until the product's expiration date.

Storage and Safety Requirement	Mandated Condition
Temperature Control	Store the product below 30 C (or 25 C), in a cool, dry place.
Environmental Protection	Must be protected from direct light and moisture and kept in a tightly closed container.
Child Safety	Mandatory instruction to keep the medicine out of the sight and reach of children at all times.

The disposal of unused or expired Ketoflex is subject to specific precautions due to the chemical profile of its components. Product disposal must be managed through approved waste disposal channels in accordance with applicable regulations. It is mandated to avoid disposing of the product into drains or general household wastewater systems.

Ketoflex